| pubmed-article:9587394 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9587394 | lifeskim:mentions | umls-concept:C0001675 | lld:lifeskim |
| pubmed-article:9587394 | lifeskim:mentions | umls-concept:C0023467 | lld:lifeskim |
| pubmed-article:9587394 | lifeskim:mentions | umls-concept:C0600558 | lld:lifeskim |
| pubmed-article:9587394 | lifeskim:mentions | umls-concept:C1292724 | lld:lifeskim |
| pubmed-article:9587394 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:9587394 | pubmed:dateCreated | 1998-6-1 | lld:pubmed |
| pubmed-article:9587394 | pubmed:abstractText | Induction therapy of acute myeloid leukaemia (AML) with standard-dose chemotherapy will result in approximately 64% of patients achieving a complete remission (CR). New drugs which are active in induction therapy in randomised clinical trials are etoposide, idarubicin and high dose cytarabine. Intensification of induction treatment with etoposide or high-dose cytarabine does not appear to alter the CR rate but prolongs remission and has some impact on survival. High-dose cytarabine in induction combinations increase relapse-free survival compared to standard approaches. These induction results appear to parallel results obtained with post-remission therapies intensified with high-dose cytarabine. These studies provide clinical evidence that intensified induction with cytarabine in AML influences subsequent outcome but is more toxic, gives more profound myelosuppression post-remission and has benefit confined to younger patients. | lld:pubmed |
| pubmed-article:9587394 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9587394 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9587394 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9587394 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9587394 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9587394 | pubmed:issn | 0001-5792 | lld:pubmed |
| pubmed-article:9587394 | pubmed:author | pubmed-author:BishopJ FJF | lld:pubmed |
| pubmed-article:9587394 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9587394 | pubmed:volume | 99 | lld:pubmed |
| pubmed-article:9587394 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9587394 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9587394 | pubmed:pagination | 133-7 | lld:pubmed |
| pubmed-article:9587394 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:9587394 | pubmed:meshHeading | pubmed-meshheading:9587394-... | lld:pubmed |
| pubmed-article:9587394 | pubmed:meshHeading | pubmed-meshheading:9587394-... | lld:pubmed |
| pubmed-article:9587394 | pubmed:meshHeading | pubmed-meshheading:9587394-... | lld:pubmed |
| pubmed-article:9587394 | pubmed:meshHeading | pubmed-meshheading:9587394-... | lld:pubmed |
| pubmed-article:9587394 | pubmed:meshHeading | pubmed-meshheading:9587394-... | lld:pubmed |
| pubmed-article:9587394 | pubmed:meshHeading | pubmed-meshheading:9587394-... | lld:pubmed |
| pubmed-article:9587394 | pubmed:meshHeading | pubmed-meshheading:9587394-... | lld:pubmed |
| pubmed-article:9587394 | pubmed:meshHeading | pubmed-meshheading:9587394-... | lld:pubmed |
| pubmed-article:9587394 | pubmed:meshHeading | pubmed-meshheading:9587394-... | lld:pubmed |
| pubmed-article:9587394 | pubmed:meshHeading | pubmed-meshheading:9587394-... | lld:pubmed |
| pubmed-article:9587394 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9587394 | pubmed:articleTitle | Approaches to induction therapy with adult acute myeloid leukaemia. | lld:pubmed |
| pubmed-article:9587394 | pubmed:affiliation | Sydney Cancer Centre, Royal Prince Alfred Hospital, Camperdown, N.S.W., Australia. jbishop@canc.rpa.cs.nsw.gov.au | lld:pubmed |
| pubmed-article:9587394 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9587394 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9587394 | pubmed:publicationType | Review | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9587394 | lld:pubmed |
